145 related articles for article (PubMed ID: 35539339)
1. Celastrol delays hepatic steatosis and carcinogenesis in a rapid AKT/c-Met-transfected hepatocellular carcinoma model
Hu J; Li X; Zhou J; Zhang C; Zheng G; Qiu Z
RSC Adv; 2018 Apr; 8(25):13976-13983. PubMed ID: 35539339
[TBL] [Abstract][Full Text] [Related]
2. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
[TBL] [Abstract][Full Text] [Related]
4. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
5. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
6. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
7. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
Zhang C; Sheng L; Yuan M; Hu J; Meng Y; Wu Y; Chen L; Yu H; Li S; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2020 Apr; 392():114918. PubMed ID: 32045588
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
10. [Antioxidant effects of celastrol against hydrogen peroxide-induced oxidative stress in the cell model of amyotrophic lateral sclerosis].
Li YH; Liu SB; Zhang HY; Zhou FH; Liu YX; Lu Q; Yang L
Sheng Li Xue Bao; 2017 Dec; 69(6):751-758. PubMed ID: 29270590
[TBL] [Abstract][Full Text] [Related]
11. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
12. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.
Saber S; Ghanim AMH; El-Ahwany E; El-Kader EMA
Cancer Chemother Pharmacol; 2020 Feb; 85(2):331-343. PubMed ID: 31989218
[TBL] [Abstract][Full Text] [Related]
13. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
14. Potential Anticancer Effect of Celastrol on Hepatocellular Carcinoma by Suppressing CXCR4-related Signal and Impeding Tumor Growth in Vivo.
Kun-Ming C; Chih-Hsien C; Chen-Fang L; Ting-Jung W; Hong-Shiue C; Wei-Chen L
Arch Med Res; 2020 May; 51(4):297-302. PubMed ID: 32169299
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of Celastrol on diethylnitrosamine-induced hepatocellular carcinoma in rats and its mechanisms.
Chang W; He W; Li PP; Song SS; Yuan PF; Lu JT; Wei W
Eur J Pharmacol; 2016 Aug; 784():173-80. PubMed ID: 27181068
[TBL] [Abstract][Full Text] [Related]
16. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo.
Rajendran P; Li F; Shanmugam MK; Kannaiyan R; Goh JN; Wong KF; Wang W; Khin E; Tergaonkar V; Kumar AP; Luk JM; Sethi G
Cancer Prev Res (Phila); 2012 Apr; 5(4):631-43. PubMed ID: 22369852
[TBL] [Abstract][Full Text] [Related]
17. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
18. The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-κb Signaling Pathways, and Inhibiting ERK Phosphorylation.
Younis NS; Ghanim AMH
Cell Biochem Biophys; 2022 Mar; 80(1):191-202. PubMed ID: 35157199
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics profiling of AKT/c-Met-induced hepatocellular carcinogenesis and the inhibitory effect of Cucurbitacin B in mice.
Ji X; Chen X; Sheng L; Deng D; Wang Q; Meng Y; Qiu Z; Zhang B; Zheng G; Hu J
Front Pharmacol; 2022; 13():1009767. PubMed ID: 36506561
[TBL] [Abstract][Full Text] [Related]
20. Anti-Tumor Effect of Celastrol on Hepatocellular Carcinoma by the circ_SLIT3/miR-223-3p/CXCR4 Axis.
Si H; Wang H; Xiao H; Fang Y; Wu Z
Cancer Manag Res; 2021; 13():1099-1111. PubMed ID: 33574707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
